Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression

American Journal of Pathology

Volumn 182, Issue 1, 2013, Pages 132-141

  Ojima, Ayako ^a   Ishibashi, Yuji ^a   Matsui, Takanori ^a   Maeda, Sayaka ^a   Nishino, Yuri ^a   Takeuchi, Masayoshi ^b   Fukami, Kei ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; CHEMOKINE RECEPTOR CCR2; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY INJURY; KIDNEY TUBULE CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; URINARY EXCRETION;

ANIMALS; ARGININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCAGON-LIKE PEPTIDE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTROPHY; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES; MACROPHAGES; MALE; PEPTIDES; PROTEIN-ARGININE N-METHYLTRANSFERASES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, GLUCAGON; RECEPTORS, IMMUNOLOGIC; REPRESSOR PROTEINS; RNA, MESSENGER; VENOMS;

EID: 84871309097     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.09.016     Document Type: Article

References (49)

1. H. Vlassara, and R. Bucala Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors Diabetes Suppl 3 1996 S65 S66
2. M. Brownlee, A. Cerami, and A. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N Engl J Med 318 1998 1315 1321
3. S. Rahbar Novel inhibitors of glycation and AGE formation Cell Biochem Biophys 48 2007 147 157 (Pubitemid 47340881)
4. Y. Yamamoto, I. Kato, T. Doi, H. Yonekura, S. Ohashi, M. Takeuchi, T. Watanabe, S. Yamagishi, S. Sakurai, S. Takasawa, H. Okamoto, and H. Yamamoto Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice J Clin Invest 108 2001 261 268 (Pubitemid 32656250)
5. T.M. Wendt, N. Tanji, J. Guo, T.R. Kislinger, W. Qu, Y. Lu, L.G. Bucciarelli, L.L. Rong, B. Moser, G.S. Markowitz, G. Stein, A. Bierhaus, B. Liliensiek, B. Arnold, P.P. Nawroth, D.M. Stern, V.D. D'Agati, and A.M. Schmidt RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy Am J Pathol 162 2003 1123 1137 (Pubitemid 36350658)
6. N. Reiniger, K. Lau, D. McCalla, B. Eby, B. Cheng, Y. Lu, W. Qu, N. Quadri, R. Ananthakrishnan, M. Furmansky, R. Rosario, F. Song, V. Rai, A. Weinberg, R. Friedman, R. Ramasamy, V. D'Agati, and A.M. Schmidt Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse Diabetes 59 2010 2043 2054
7. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299 (Pubitemid 40872698)
8. S. Yamagishi, and T. Matsui Advanced glycation end products, oxidative stress and diabetic nephropathy Oxid Med Cell Longev 3 2010 101 108
9. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
10. M.S. Winzell, and B. Ahrén G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes Pharmacol Rev 116 2007 437 448 (Pubitemid 350116941)
11. R. Chilton, J. Wyatt, S. Nandish, R. Oliveros, and M. Lujan Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies Am J Med 124 1 Suppl 2011 S35 S53
12. P. Anagnostis, V.G. Athyros, F. Adamidou, A. Panagiotou, M. Kita, A. Karagiannis, and D.P. Mikhailidis Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control Diabetes Obes Metab 13 2011 302 312
13. C. Baylis Nitric oxide deficiency in chronic kidney disease Am J Physiol Renal Physiol 294 2008 F1 F9
14. S. Yamagishi, and T. Matsui Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy: friend or foe? Pharmacol Res 64 2011 187 194
15. S. Yamagishi, S. Ueda, K. Nakamura, T. Matsui, and S. Okuda Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications Curr Pharm Des 14 2008 2613 2618
16. R.H. Böger, S.M. Bode-Böger, and J.C. Frölich The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications Atherosclerosis 127 1996 1 11 (Pubitemid 26425836)
17. L. Tarnow, P. Hovind, T. Teerlink, C.D. Stehouwer, and H.H. Parving Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes Diabetes Care 27 2004 765 769 (Pubitemid 38280547)
18. T. Nakamura, E. Sato, N. Fujiwara, Y. Kawagoe, Y. Ueda, T. Suzuki, S. Yamada, M. Takeuchi, K. Fukami, S. Ueda, H. Adachi, T. Matsui, S. Okuda, and S. Yamagishi Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients Metabolism 58 2009 1624 1628
19. M. Takeuchi, Z. Makita, R. Bucala, T. Suzuki, T. Koike, and Y. Kameda Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo Mol Med 6 2000 114 125
20. S. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, Y. Jinnouchi, Y. Yoshida, T. Matsuura, I. Narama, Y. Motomiya, M. Takeuchi, H. Inoue, A. Yoshimura, R. Bucala, and T. Imaizumi Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J Biol Chem 281 2006 20213 20220 (Pubitemid 44065796)
21. S. Yamagishi, H. Yonekura, Y. Yamamoto, K. Katsuno, F. Sato, I. Mita, H. Ooka, N. Satozawa, T. Kawakami, M. Nomura, and H. Yamamoto Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor J Biol Chem 272 1997 8723 8730 (Pubitemid 27147841)
22. N. Sasaki, M. Takeuchi, H. Chowei, S. Kikuchi, Y. Hayashi, N. Nakano, H. Ikeda, S. Yamagishi, T. Kitamoto, T. Saito, and Z. Makita Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques Neurosci Lett 326 2002 117 120 (Pubitemid 34607573)
23. S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, and M. Takeuchi Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells Kidney Int 63 2003 464 473 (Pubitemid 36126793)
24. Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamagishi Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression Biochem Biophys Res Commun 391 2010 1405 1408
25. T. Yoshida, S. Yamagishi, K. Nakamura, T. Matsui, T. Imaizumi, M. Takeuchi, H. Koga, T. Ueno, and M. Sata Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation Diabetologia 49 2006 3094 3099 (Pubitemid 44730314)
26. T. Fujimura, S. Yamagishi, S. Ueda, K. Fukami, R. Shibata, Y. Matsumoto, Y. Kaida, A. Hayashida, K. Koike, T. Matsui, K. Nakamura, and S. Okuda Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats Nephrol Dial Transplant 24 2009 1397 1406
27. T.J. Kieffer, and J.F. Habener The glucagon-like peptides Endocr Rev 20 1999 876 913 (Pubitemid 30647076)
28. S. Maeda, T. Matsui, M. Takeuchi, Y. Yoshida, R. Yamakawa, K. Fukami, and S. Yamagishi Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis Pharmacol Res 63 2011 241 248
29. T. Matsui, Y. Nishino, M. Takeuchi, and S. Yamagishi Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis Pharmacol Res 63 2011 383 388
30. S. Ueda, S. Yamagishi, Y. Kaida, and S. Okuda Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease Nephrology (Carlton) 12 2007 582 590 (Pubitemid 350059125)
31. C. Zoccali, F.A. Benedetto, R. Maas, F. Mallamaci, G. Tripepi, L.S. Malatino, R. Böger CREED Investigators Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease J Am Soc Nephrol 13 2002 490 496 (Pubitemid 34106292)
32. C. Zoccali, F. Mallamaci, R. Maas, F.A. Benedetto, G. Tripepi, L.S. Malatino, A. Cataliotti, I. Bellanuova, R. Böger CREED Investigators Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine in hemodialysis patients Kidney Int 62 2002 339 345 (Pubitemid 34754080)
33. J.M. Cross, A. Donald, P.J. Vallance, J.E. Deanfield, R.G. Woolfson, and R.J. MacAllister hemodialysis improves endothelial function in humans Nephrol Dial Transplant 16 2001 1823 1829 (Pubitemid 32821414)
34. K. Caglar, M.I. Yilmaz, A. Sonmez, E. Cakir, A. Kaya, C. Acikel, T. Eyileten, M. Yenicesu, Y. Oguz, C. Bilgi, C. Oktenli, A. Vural, and C. Zoccali ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease Kidney Int 70 2006 781 787 (Pubitemid 44215355)
35. D. Fliser, F. Kronenberg, J.T. Kielstein, C. Morath, S.M. Bode-Boger, H. Haller, and E. Ritz Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study J Am Soc Nephrol 16 2005 2456 2461 (Pubitemid 41725064)
36. S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, and H. Yamamoto Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells Diabetologia 41 1998 1435 1441 (Pubitemid 28551614)
37. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, M. Takeuchi, and Z. Makita Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes Mol Med 8 2002 546 550 (Pubitemid 36332366)
38. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression Pharmacol Res 61 2010 34 39
39. H. Hendarto, T. Inoguchi, Y. Maeda, N. Ikeda, J. Zheng, R. Takei, H. Yokomizo, E. Hirata, N. Sonoda, and R. Takayanagi GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases Metabolism 61 10 2012 1422 1434
40. S.J. Jia, D.J. Jiang, C.P. Hu, X.H. Zhang, H.W. Deng, and Y.J. Li Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells Vascul Pharmacol 44 2006 143 148
41. R.H. Böger, K. Sydow, J. Borlak, T. Thum, H. Lenzen, B. Schubert, D. Tsikas, and S.M. Bode-Böger LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases Circ Res 87 2000 99 105 (Pubitemid 30616904)
42. M. Sharma, E.T. McCarthy, V.J. Savin, and E.A. Lianos Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide Kidney Int 68 2005 2735 2744 (Pubitemid 43251018)
43. N. Banba, T. Nakamura, M. Matsumura, H. Kuroda, Y. Hattori, and K. Ksai Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy Kidney Int 58 2000 684 960
44. H. Sugimoto, K. Shikata, K. Hirata, K. Akiyama, M. Matsuda, M. Kushiro, Y. Shikata, N. Miyatake, M. Miyasaka, and H. Makino Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation Diabetes 46 1997 2075 2201
45. F.Y. Chow, D.J. Nikolic-Paterson, E. Ozols, R.C. Atkins, and G.H. Tesch Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice J Am Soc Nephrol 16 2005 1711 1722 (Pubitemid 41716477)
46. S.D. Ye, M. Zheng, L.L. Zhao, Y. Qian, X.M. Yao, A. Ren, S.M. Li, and C.Y. Jing Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy Eur J Clin Invest 39 2009 980 985
47. M. Chen, Y. Li, T. Yang, Y. Wang, Y. Bai, and X. Xie ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells Cytokine 43 2008 149 159
48. Y.H. Chen, X. Xu, M.J. Sheng, Z. Zheng, and Q. Gu Effects of asymmetric dimethylarginine on bovine retinal capillary endothelial cell proliferation, reactive oxygen species production, permeability, intercellular adhesion molecule-1, and occludin expression Mol Vis 17 2011 332 340
49. M. Takeuchi, Z. Makita, K. Yanagisawa, K. Kameda, and T. Koike Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients Mol Med 5 1999 393 405 (Pubitemid 29382313)